marijuanaBenzodiazepinesCocaineheroinpain killersfaqabout uscontact us
Study Name Who's Treated? Age Treatment components Duration Study Status
Quetiapine for Marijuana Dependence Marijuana users 18-60 Quetiapine (Seroquel®) or placebo (double-blind)

Individual sessions of medical management therapy weekly
12 week outpatient medication trial requiring 2 clinic visits per week Active and recruiting participants

Quetiapine Pharmacotherapy for Cannabis Dependence

The purpose of this research study is to evaluate the efficacy of quetiapine for the treatment of marijuana dependence. Quetiapine is not currently approved by the FDA for this purpose and has not been studied for marijuana dependence. It is FDA-approved for bipolar disorder and schizophrenia.

Type of Treatment:
This study involves 12 weeks of outpatient medication treatment requiring clinic visits twice a week. At each clinic visit vital signs will be checked, questionnaires completed and a urine sample collected. Once per week, in a 30-minute session the psychiatrist will perform study evaluations and work on treatment goals.Medication will be dispensed once per week during a study visit to be taken at home daily.After the study is finished, patients are able to continue meeting with psychiatrist for 4 weeks. This is to go over progress made during the trial and to find referrals for continued treatment if requested.

The Substance Treatment and Research Service of Columbia University (STARS) provides free and confidential treatment of substance abuse in the context of a research treatment clinical trial.

Cutting edge approaches to treating addiction to marijuana, benzodiazepines, cocaine, heroin or narcotic painkillers are available in a supportive and professional environment.
Study participation in all trials is FREE and transportation costs will be reimbursed. Call 212-923-3031 to schedule an appointment today.